Compatibility «Ritonavir» and «Darunavir»
Between «Ritonavir» and «Darunavir» found 27 dangerous and 82 negative interactions, joint admission is not recommended without consulting a doctor.
-
Interactions Ritonavir with Darunavir
-
Dangerous interactions
Therefore, the simultaneous use of a combination of darunavir + ritonavir in doses other than 600/100 mg 2 times a day and elvitegravir is not recommended. Simultaneous use of a combination of darunavir + ritonavir and elvitegravir in the presence of cobicistat is not recommended. Simultaneous use of a combination of darunavir + ritonavir and delavirdine is not recommended. It is not recommended to use saquinavir simultaneously with darunavir, regardless of the use of a small additional dose of ritonavir. When used in combination with the combination of darunavir + ritonavir, the dose of indinavir in patients who do not tolerate it well can be reduced from 800 mg 2 times a day to 600 mg 2 times a day. Concomitant use of alfuzosin and the combination of darunavir + ritonavir is contraindicated. The simultaneous use of ranolazine and the combination of darunavir + ritonavir is contraindicated. The simultaneous use of a combination of darunavir + ritonavir with amiodarone, bepridil, dronedarone, quinidine and lidocaine with their systemic administration is contraindicated. It is not recommended to use the combination of darunavir + ritonavir and rivaroxaban at the same time. The combination of darunavir + ritonavir is not recommended to be used in combination with these drugs, since this can cause a significant decrease in the concentration of darunavir in plasma and, consequently, a decrease in its therapeutic effect. Simultaneous use of the combination of darunavir + ritonavir with astemizole and terfenadine is contraindicated. The use of a combination of darunavir + ritonavir with oral midazolam or triazolam is contraindicated. Simultaneous use of pimozide and the combination of darunavir + ritonavir is contraindicated. Concomitant use of sertindole and the combination of darunavir + ritonavir is contraindicated. The simultaneous use of a combination of darunavir + ritonavir and quetiapine is contraindicated, as this may lead to an increase in the toxicity associated with quetiapine. In patients with reduced kidney or liver function, colchicine is contraindicated when used in combination with the combination of darunavir + ritonavir. Simultaneous administration of the combination of darunavir + ritonavir with telaprevir is not recommended. It is not recommended to use simeprevir and the combination of darunavir + ritonavir simultaneously. The combination of darunavir + ritonavir should not be used in conjunction with drugs containing St. John's wort extract. The use of a combination of darunavir + ritonavir simultaneously with lovastatin or simvastatin is contraindicated. Voriconazole should not be used simultaneously with the combination of darunavir + ritonavir, simultaneous use is possible only if the potential benefit from the use of voriconazole exceeds the potential risk. Thus, the simultaneous use of a combination of darunavir + ritonavir and sildenafil in the treatment of pulmonary arterial hypertension is contraindicated. For patients receiving tadalafil and starting therapy with the combination of darunavir + ritonavir, tadalafil should be discontinued at least 24 hours before the start of therapy with the combination of darunavir + ritonavir and simultaneous use of tadalafil should be avoided during the start of therapy with this combination. The combined use of rifampicin and the combination of darunavir + ritonavir is contraindicated. The simultaneous use of everolimus and the combination of darunavir + ritonavir is not recommended. The simultaneous use of ergot alkaloids and the combination of darunavir + ritonavir is contraindicated. Concomitant use of cisapride and the combination of darunavir + ritonavir is contraindicated. -
Negative interactions
When ritonavir is co-administered with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir and tipranavir), full information on the appointment of a specific protease inhibitor, including important information on drug interactions, should be read. Detailed information about the co-administration with ritonavir can be found in the instructions for the medical use of fosamprenavir, atazanavir, darunavir. Ritonavir and Darunavir belong to the same pharmaceutical group: Drugs for the treatment of HIV infection. Ritonavir and Darunavir belong to the same pharmaceutical group: HIV protease inhibitors. Darunavir, used in combination with ritonavir, is an inhibitor of the isoenzymes CYP3A, CYP2D6 and the P-gp transporter. The simultaneous use of a combination of darunavir + ritonavir and drugs, which are metabolized mainly by CYP3A, CYP2D6 isoenzymes and are tolerated by P-gp, may cause an increase in plasma concentrations of such drugs, which, in turn, may cause an increase or prolongation of the therapeutic effect, as well as the appearance of side effects. No dose adjustment of darunavir is required when combined with a low dose of ritonavir and raltegravir. The results of the study of the interaction between tenofovir (tenofovir disoproxil fumarate 300 mg/day) and the combination of darunavir + ritonavir (300/100 mg 2 times a day) showed that the concentration of tenofovir in plasma increased by 22%. Other NIOT (zidovudine, zalcitabine, emtricitabine, stavudine, lamivudine and abacavir) are eliminated mainly by the kidneys, and therefore the probability of their interaction with the combination of darunavir + ritonavir is negligible. Simultaneous use of a combination of darunavir + ritonavir and delavirdine may lead to an increase in the concentration of darunavir and delavirdine due to inhibition of the CYP3A isoenzyme. When studying the interaction of the combination of darunavir + ritonavir (600/100 mg 2 times a day) and etravirine, a decrease in the concentration of etravirine by 37% was found and no significant changes in the concentration of darunavir were found. An interaction study was conducted between the combination of darunavir + ritonavir (300/100 mg 2 times a day) and efavirenz (600 mg 1 time a day). The plasma concentration of efavirenz increased by 21% when it was used simultaneously with the combination of darunavir + ritonavir. The results of the study of the interaction between the combination of darunavir + ritonavir (400/100 mg 2 times a day) and nevirapine (200 mg 2 times a day) showed that the plasma concentration of darunavir did not depend on the presence of nevirapine. However, when used concomitantly with the combination of darunavir + ritonavir, the concentration of nevirapine in plasma increased by 27% (compared with the control). The results of the study of the interaction between the combination of darunavir + ritonavir (800/100 mg 1 time per day) with rilpivirine (150 mg 1 time per day) did not show a clinically significant effect on the concentration of darunavir. In general, the effect of improving the pharmacokinetics of darunavir with ritonavir was manifested in the fact that plasma concentrations of darunavir increased approximately 14 times after taking one dose of darunavir (600 mg) and 100 mg of ritonavir 2 times a day. Therefore, darunavir should be used in combination with a low dose of ritonavir to increase the bioavailability of darunavir. The results of the study of the interaction between the combination of darunavir + ritonavir (1200/100 mg 2 times a day) or 1200 mg of darunavir without ritonavir and the combination of lopinavir + ritonavir (400/100 mg 2 times a day or 533/133.3 mg 2 times a day) showed that in the presence of the combination of lopinavir + ritonavir, the concentration of darunavir in plasma decreased by 40%. A study of the interaction of darunavir (400 mg 2 times a day), saquinavir (1000 mg 2 times a day) and ritonavir (100 mg 2 times a day) showed that the concentration of darunavir in plasma decreased by 26% in the presence of saquinavir and ritonavir; the combination of darunavir + ritonavir did not affect the concentration of saquinavir in plasma. In a study of the interaction between the combination of darunavir + ritonavir (400/100 mg 2 times a day) and indinavir (800 mg 2 times a day), the plasma concentration of darunavir increased by 24% in the presence of indinavir and ritonavir; in the presence of the combination of darunavir + ritonavir, the plasma concentration of indinavir increased by 23%. In the study of the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and maraviroc (150 mg 2 times a day), the concentration of maraviroc increased by 305%. The concentration of alfuzosin in plasma may increase when used concomitantly with the combination of darunavir + ritonavir. The concentration of ranolazine in plasma may increase when used concomitantly with the combination of darunavir + ritonavir due to inhibition of CYP3A isoenzymes. In all studies on the interaction of the combination of darunavir + ritonavir (600/100 mg 2 times a day) and a single dose of digoxin (0.4 mg), an increase in the final concentration of digoxin in plasma by 77% was shown. The combination of darunavir + ritonavir and dabigatran should be used with caution and is not recommended in patients with severe renal insufficiency. A study of the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and carbamazepine (200 mg 2 times a day) showed that the concentration of darunavir in this case does not change, while the concentration of ritonavir decreases by 49%. No dose adjustment is required for the combination of darunavir + ritonavir. If it is necessary to use the combination of darunavir + ritonavir and carbamazepine simultaneously, patients should be monitored due to the possibility of side effects of carbamazepine use. Thus, carbamazepine doses can be reduced by 25-50% when combined with the combination of darunavir + ritonavir. With the simultaneous use of these antihistamines with the combination of darunavir + ritonavir, the concentration of antihistamines in plasma may increase. When studying the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and the combination of artemether + lumefantrin (80/480 mg, 6 doses taken at 0, 8, 24, 36, 48 and 60 hours), an increase in the concentration of lumefantrin by 2.75 times was shown, while the concentration of darunavir did not change. A study of the interaction between paroxetine (20 mg 1 time per day) or sertraline (50 mg 1 time per day) and the combination of darunavir + ritonavir (400/100 mg 2 times per day) showed that the concentration of darunavir in plasma did not depend on the presence of sertraline or paroxetine. In addition, in patients receiving a stable dose of sertraline or paroxetine, who are being treated with a combination of darunavir + ritonavir, it is necessary to carefully monitor the severity of the main effect of the antidepressant. The combined use of a combination of darunavir + ritonavir with the above antidepressants may cause an increase in the concentration of the antidepressant in plasma due to inhibition of CYP2D6 and/or CYP3A4 isoenzymes. If it is necessary to use these drugs together with the combination of darunavir + ritonavir, it is recommended to conduct clinical monitoring of the patient's condition, it may be necessary to adjust the dose of the antidepressant. The combined use of a combination of darunavir + ritonavir with these sedative/ hypnotic drugs may lead to an increase in their plasma concentration due to inhibition of CYP3A isoenzymes. With the combined use of risperidone or thiorizadine with the combination of darunavir + ritonavir, their plasma concentrations may increase, as a result of which, when used together, the doses of risperidone and thiorizadine should be reduced. When quetiapine is co-administered with the combination of darunavir + ritonavir, the concentration of quetiapine in plasma may increase due to the inhibition of CYP3A isoenzymes by darunavir. When colchicine is co-administered with the combination of darunavir + ritonavir, the concentration of colchicine in plasma may increase. The concentration of BCC in plasma may increase when used concomitantly with the combination of darunavir + ritonavir due to inhibition of CYP3A and/or CYP2D6 isoenzymes. A study of the interaction between the combination of darunavir + ritonavir (400/100 mg 2 times a day) and clarithromycin (500 mg 2 times a day) showed that the concentration of clarithromycin in plasma increased by 57%, while the concentration of darunavir remained unchanged. For patients taking bosentan and starting therapy with the combination of darunavir + ritonavir, it is recommended to cancel bosentan at least 36 hours before starting therapy with this combination. In a study on the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and boceprevir (800 mg 3 times a day), the concentration of darunavir decreased by 44%, and the concentration of boceprevir decreased by 32%. Thus, it is not recommended to use the combination of darunavir + ritonavir together with boceprevir. In studies of the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and telaprevir (750 mg every 8 hours), the concentration of darunavir decreased by 40%, and the concentration of telaprevir - by 35%. With simultaneous use of simeprevir and the combination of darunavir + ritonavir (800/100 mg/ day), plasma concentrations of darunavir and simeprevir increased due to inhibition of CYP3A isoenzymes. In clinical studies of the interaction of the combination of darunavir + ritonavir and simeprevir, the concentration of the latter in plasma increased by 2.59 times, the concentration of darunavir - by 1.18 times. St. John's wort extract lowers the concentrations of darunavir and ritonavir in blood plasma (induction of liver enzymes). The concentration of darunavir (as well as the concentration of ritonavir) may increase after discontinuation of drugs containing St. John's wort extract. CYP3A isoenzymes play an important role in the metabolism of statins such as simvastatin and lovastatin, therefore, the concentration of these drugs in plasma can significantly increase when used simultaneously with the combination of darunavir + ritonavir. A study of the interaction between atorvastatin (10 mg 1 time per day) and the combination of darunavir + ritonavir (300/100 mg 2 times per day) showed that in this situation, the concentration of atorvastatin in plasma was only 15% lower than with atorvastatin monotherapy (40 mg 1 time per day). The combination of darunavir + ritonavir (600/100 mg 2 times a day) increased the concentration of pravastatin in plasma after taking a single dose of this drug (40 mg) by about 80%, but only in some patients. If necessary, the combined use of pravastatin and the combination of darunavir + ritonavir is recommended to start taking pravastatin with the lowest possible dose and increase it until a clinical effect appears, controlling the manifestation of side effects of pravastatin. A study of the interaction between the combination of darunavir + ritonavir (600/100 mg) with rosuvastatin (10 mg) revealed an increase in the concentration of rosuvastatin. If it is necessary to use rosuvastatin and the combination of darunavir + ritonavir simultaneously, it is recommended to start with the lowest dose of rosuvastatin, gradually increasing the dose until a clinical effect is obtained, constantly monitoring the safety of therapy. A study of the interaction between the combination of darunavir + ritonavir (800/100 mg/day) and pitavastatin (4 mg/day) revealed a decrease in the concentration of pitavastatin in plasma, which is not considered clinically significant. Simultaneous use of salmeterol and the combination of darunavir + ritonavir is not recommended, etc.; the risk of side effects of salmeterol from the side of the cardiovascular system may increase, in pm, prolongation of the QT interval, palpitations and sinus tachycardia. The systemic use of these antifungal drugs simultaneously with the combination of darunavir + ritonavir may lead to an increase in plasma concentrations of darunavir. This was confirmed by a study of the interaction between ketoconazole (200 mg 2 times a day) and the combination of darunavir + ritonavir (400/100 mg 2 times a day), in which the concentrations of ketoconazole and darunavir increased by 212 and 42%, respectively. When using the combination of darunavir + ritonavir and posaconazole simultaneously, it is recommended to conduct clinical monitoring of the patient's condition. The concentration of voriconazole in plasma may decrease when combined with the combination of darunavir + ritonavir. When using clotrimazole and the combination of darunavir + ritonavir together, caution should be exercised, and it is also recommended to conduct constant clinical monitoring of the patient. The combined use of beta-blockers and the combination of darunavir + ritonavir may lead to an increase in the concentration of beta-blockers due to inhibition of the CYP2D6 isoenzyme. With the simultaneous use of these drugs and the combination of darunavir + ritonavir, caution should be exercised and careful clinical monitoring should be carried out. In a study of the effect of the combination of darunavir + ritonavir (600/100 mg 2 times a day) on stable maintenance therapy with methadone, a 16% decrease in the concentration of R-methadone in plasma was shown. Based on pharmacokinetic and clinical results, dose adjustment of methadone during initiation of therapy with the combination of darunavir + ritonavir is not required. When taking the combination of darunavir + ritonavir and buprenorphine together, careful clinical monitoring is recommended. The results of a study on the interaction between the combination of darunavir + ritonavir (600/100 mg 2 times a day) and ethinyl estradiol and norethisterone indicate that the constant plasma concentration of ethinyl estradiol and norethisterone decreases by 44 and 14%, respectively. In one study, sildenafil concentrations were studied after taking one dose of this drug (100 mg), as well as after taking 25 mg of sildenafil simultaneously with the combination of darunavir + ritonavir (400/100 mg 2 times a day). Caution should be exercised when concomitantly using PDE-5 inhibitors for the treatment of erectile dysfunction and the combination of darunavir + ritonavir. A safe and effective dose of sildenafil for the treatment of pulmonary arterial hypertension when used concomitantly with the combination of darunavir + ritonavir has not been established. For the treatment of pulmonary arterial hypertension with tadalafil, concomitant use with the combination of darunavir + ritonavir requires a change in the doses of tadalafil. 1 week after the start of therapy with the combination of darunavir + ritonavir, tadalafil should be resumed at a dose of 20 mg 1 time per day with a possible increase to 40 mg 1 time per day based on individual tolerability. In studying the interaction of the combination of darunavir + ritonavir (600/100 mg 2 times a day) and rifabutin (150 mg every other day), an increase in the concentration of darunavir by 57% was observed. The study of the interaction showed comparable concentrations when using 300 mg of rifabutin once a day and 150 mg every other day together with the combination of darunavir + ritonavir (600/100 mg 2 times a day), as well as an increase in the concentration of the active metabolite 25-O-deacetylrifabutin. When trying to compensate for this decrease in concentration by increasing the dose of other protease inhibitors taken with a low dose of ritonavir, liver reactions were observed (increased activity of liver enzymes). The combined use of rifapentin and the combination of darunavir + ritonavir is not recommended. With the simultaneous use of a combination of darunavir + ritonavir and these antitumor drugs, an increase in plasma concentrations of the latter is expected due to inhibition of CYP3A isoenzymes, which can cause undesirable reactions usually associated with taking these drugs. Caution is recommended when using the combination of darunavir + ritonavir and these antitumor drugs simultaneously. The concentration of ergot alkaloids in plasma may increase when used concomitantly with the combination of darunavir + ritonavir. The concentration of cisapride in plasma may increase when used concomitantly with the combination of darunavir + ritonavir. -
No interactions
Simultaneous use with other antiretroviral drugs. The combination of darunavir + ritonavir (600/100 mg 2 times a day) did not have a clinically significant effect on the concentration of dolutegravir in plasma. With the simultaneous use of a combination of darunavir + ritonavir and dolutegravir, no dose adjustment is required. With the simultaneous use of a combination of darunavir + ritonavir (600/100 mg 2 times a day) and elvitegravir, the dose of elvitegravir should be 150 mg 1 time per day. The combination of darunavir + ritonavir (600/100 mg 2 times a day) simultaneously with didanosine can be used without dose adjustment. With the simultaneous use of a combination of darunavir + ritonavir and tenofovir, dose adjustment is not required. Thus, the combination of darunavir + ritonavir can be simultaneously prescribed with 200 mg of etravirine 2 times a day without changing the dose. This interaction is not clinically significant, and therefore the combination of darunavir + ritonavir and efavirenz can be used simultaneously without dose adjustment. This interaction is considered clinically insignificant, and therefore the combination of darunavir + ritonavir and nevirapine can be used simultaneously without changing their doses. The concentration of rilpivirine increased by 130% when used concomitantly with the combination of darunavir + ritonavir. This interaction is considered clinically insignificant, and therefore the combination of darunavir + ritonavir and rilpivirine can be used simultaneously without changing their doses. A study of the interaction between the combination of darunavir + ritonavir (400/100 mg 2 times a day) and atazanavir (300 mg 1 time a day) showed no significant change in plasma concentrations of darunavir and atazanavir when used simultaneously. With simultaneous use of the combination darunavir + ritonavir maraviroc should be prescribed at a dosage of 150 mg 2 times a day. The effect of maraviroc on the concentration of darunavir/ritonavir was not noted. No interaction is expected between the combination of darunavir + ritonavir and antacid drugs. The combination of darunavir + ritonavir and antacid drugs can be used simultaneously without dose adjustment. The simultaneous use of ranitidine (150 mg 2 times a day) and the combination of darunavir + ritonavir (400/100 mg 2 times a day) had no effect on the concentration of darunavir in plasma. The combination of darunavir + ritonavir and H2 receptor antagonists can be used simultaneously without dose adjustment. The simultaneous use of omeprazole (20 mg per day) and the combination of darunavir + ritonavir (400/100 mg 2 times a day) had no effect on the concentration of darunavir in plasma. The combination of darunavir + ritonavir and proton pump inhibitors can be used simultaneously without dose adjustment. With the simultaneous use of a combination of darunavir + ritonavir and the above anticoagulants, the concentration of the anticoagulant in plasma may increase due to inhibition of CYP3A or P-gp isoenzymes. In cases where SSRIs have to be used simultaneously with darunavir and ritonavir, it is necessary to carefully select the dose of these inhibitors based on a clinical assessment of the antidepressant effect. With simultaneous use of bosentan and the combination of darunavir + ritonavir, the concentration of bosentan in plasma may increase. With simultaneous use of systemic or inhaled/nasal budesonide, fluticasone or prednisone and the combination of darunavir + ritonavir, the concentration of these GCS in plasma may increase. Clinical monitoring should be carried out with simultaneous use of prednisone and the combination of darunavir + ritonavir. The combination of darunavir + ritonavir and pitavastatin can be used simultaneously without dose adjustment. Plasma concentrations of cyclosporine, tacrolimus and sirolimus may increase if these drugs are used simultaneously with the combination of darunavir + ritonavir. Simultaneous use of the combination of darunavir + ritonavir and everolimus is not recommended. If it is necessary to use a combination of darunavir + ritonavir simultaneously with ketoconazole or itraconazole, the daily dose of the latter should not exceed 200 mg. The results of the study of the interaction of the combination of darunavir + ritonavir with buprenorphine/naloxone demonstrated the absence of an effect of the combination of darunavir + ritonavir on the concentration of buprenorphine when used together. If it is necessary to use darunavir and ritonavir simultaneously with sildenafil, vardenafil or tadalafil, a single dose of sildenafil should not exceed 25 mg for 48 hours, a single dose of vardenafil should not exceed 2.5 mg for 72 hours, and a single dose of tadalafil should not exceed 10 mg for 72 hours. Simultaneous use of the combination of darunavir + ritonavir and avanafil is not recommended. -
Positive interactions
Didanosine is recommended to be used on an empty stomach or 1 hour before or 2 hours after taking the combination darunavir + ritonavir, which is taken with meals. It is recommended to initially prescribe a minimum dose of digoxin and measure its concentration in blood serum to obtain the desired clinical effect when used simultaneously with the combination of darunavir + ritonavir. The recommended dose of apixaban when used concomitantly with the combination of darunavir + ritonavir is 2.5 mg 2 times a day. With the simultaneous use of a combination of darunavir + ritonavir and pimozide, it is possible to increase the concentration of pimozide in plasma due to inhibition of CYP3A and CYP2D6 isoenzymes. In the treatment of exacerbations of gout for patients receiving a combination of darunavir + ritonavir, the recommended dose of colchicine is 0.6 mg, followed by 0.3 mg after 1 hour. To prevent exacerbations in patients receiving the combination darunavir + ritonavir, the recommended dose of colchicine is 0.3 mg every day or every other day. Patients receiving the combination of darunavir + ritonavir for at least 10 days are recommended an initial dose of bosentan 62.5 mg every day or every other day, depending on individual tolerability. If it is necessary to use atorvastatin and the combination of darunavir + ritonavir simultaneously, it is recommended to start with a dose of atorvastatin 10 mg 1 time per day. For patients receiving the combination of darunavir + ritonavir for at least one week, the initial dose of tadalafil should be 20 mg once a day, with a possible increase to 40 mg once a day based on individual tolerability. Based on the safety profile of the darunavir + ritonavir combination, an increase in the concentration of darunavir in the presence of rifabutin does not require dose adjustment for the combination of darunavir + ritonavir. -
Unclear interactions
HIV-1 protease inhibitors atazanavir, darunavir, fosamprenavir. ↑Darunavir. Suitable doses of the combination of darunavir + ritonavir and delavirdine have not been established. Ritonavir. The combination of darunavir + ritonavir may increase serum concentrations of these antiarrhythmic drugs. The combination of darunavir + ritonavir may affect plasma warfarin concentrations. Phenobarbital and phenytoin are inducers of CYP450 isoenzymes. On the other hand, in the presence of a combination of darunavir + ritonavir, plasma concentrations of sertraline and paroxetine decreased by 49 and 39%, respectively. In the treatment of familial Mediterranean fever in patients receiving a combination of darunavir + ritonavir, the maximum dose of colchicine should be 0.6 mg once a day (or 0.3 mg 2 times a day). At least 10 days after the start of therapy with the combination of darunavir + ritonavir, bosentan should be continued at a dosage of 62.5 mg every day or every other day, depending on individual tolerability.
-
Dangerous interactions
Decoding the colors of interactions and contraindications
Dangerous | — | a pronounced negative interaction or contraindication. |
Negative | — | negative interaction or side effect that may reduce effectiveness. |
Positive | — | the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication of the drug. |
No | — | the drugs do NOT interact, which is separately indicated in the instructions. |
Unclear | — | the system failed to pre-assess the danger. |
Video instruction
Additional information
- Kiberis checks interactions and evaluates drug compatibility online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
- Why do I need to
- Avoid dangerous prescriptions for your patients.
- Check the contraindications.
- Evaluate the safety of therapy in the treatment of children.
- See the compatibility of drugs with alcohol (enter it as a drug).
- Point the doctor to the found interaction - you may need to adjust the therapy.
- The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
- The article is written: artificial intelligence Kiberis
- Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
- Total analyzed: 169,974,420 possible combinations of drugs and their components were found 412,510 interacting combinations.
- Medicine section: Standard evidence-based medicine
- The date of the last update of the interaction database: 2024-05-02
Category - medicine